Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Bristol Myers to pay up to $1.56 billion to develop, sell Agenus's cancer therapy

Published 05/18/2021, 08:36 AM
Updated 05/19/2021, 06:32 AM
© Reuters. The logo of U.S. drugmaker Bristol Myers Squibb.   via REUTERS
BMY
-
AGEN
-

(This May 18 story corrects payment value in headline and first paragraph to $1.56 billion from $1.38 billion)

(Reuters) - Drugmaker Bristol Myers (NYSE:BMY) Squibb will pay biotech firm Agenus (NASDAQ:AGEN) Inc up to $1.56 billion to exclusively develop and commercialize its experimental cancer drug, AGEN1777, the companies said on Tuesday.

The drug candidate, primarily being tested to improve anti-tumor activity, will also be studied and developed by Bristol Myers for immuno-oncology treatments including non-small cell lung cancer, which accounts for about 85% of lung cancer cases globally.

Bristol Myers has been betting on sales of its Opdivo drug to treat such cancers, but that market is currently dominated by Merck & Co's rival treatment Keytruda.

Agenus will receive up to $1.36 billion in development, regulatory and commercial milestones in addition to double-digit royalties on net product sales. It will receive an upfront payment of $200 million. (https://refini.tv/2STY2pX)

© Reuters. The logo of U.S. drugmaker Bristol Myers Squibb.   via REUTERS

The biotech company will retain options to conduct clinical studies under the development plan, and to test it in combination with certain other pipeline assets, and will co-promote AGEN1777 in the United States after commercialization.

Agenus plans to file application to begin human trials for the therapy with the U.S. Food and Drug Administration in the second quarter of this year, the company said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.